Niacinamide glycolate | 683226-77-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Niacinamide glycolate
• 英文别名: 2-hydroxyacetic acid;pyridine-3-carboxamide
• CAS: 683226-77-9
• 化学式: C₂H₄O₃*2C₆H₆N₂O
• 分子量: 320.305
• InChiKey: ZUWUQLAVERUBMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.76
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  羟基乙酸 、 烟酰胺 以 乙酸乙酯 为溶剂， 反应 48.0h， 生成 Niacinamide glycolate
  参考文献：
  名称：

  涉及乙醇酸的药物共晶体中的反复基序：X射线表征，Hirshfeld表面分析和DFT计算

  摘要：

  在过去的几十年中，通过明确的分子间作用力将化合物结合在一个晶格中以形成药物传递相关特征的可能性，例如溶解性推动了学术界和制药业中晶体工程的发展。如果两种成分均具有生物活性并具有良好的耐受性，则共晶方法特别有用。制备了乙醇酸（GA）与吡啶甲酸酰胺（PA），烟酰胺（NA），异烟酰胺（INA），咖啡因（CA），茶碱（TP）与甲酰胺（FA）的共结晶以及乙醇酸铵与乙醇酸的共结晶，并通过元素分析，X射线粉末衍射，IR和NMR光谱以及单晶X射线衍射进行表征。制备的化合物的组成为[NH 4 ] [GA-H]·（GA）（1），（PA）/（GA）（2），2（NA）/（GA）（3），（IN）/ （GA）（4），（CA）/ 2（GA）（5）和（TP）·（FA）（6）。自组装的超分子结构受氢键控制，在某些情况下受芳族供体-受体相互作用的控制。晶体结构分析表明存在特征性杂合子，具有氢键基序R 2 2（8）（伯酰胺-羧

  DOI：

  10.1039/d0ce01064b

文献信息

• Ion-pair delivery system for cosmetic and pharmaceutical compositions
  申请人：——

  公开号：US20040228884A1

  公开（公告）日：2004-11-18

  This invention relates to a novel ion-pair delivery system useful for cosmetic, pharmaceutical, and topical nutraceutical applications in which the functional performance and consumer aesthetics of an electron donor composition and an electron acceptor composition, or a proton donor composition and a proton acceptor composition, are synergistically enhanced when such compositions are combined in an ion-pair mode. During ion-pair bonding process, the electron donor composition or the proton acceptor composition become positively charged and the electron acceptor composition or proton donor composition become negatively charged and thus bind together in an ionic manner. Such ion-pair compositions release their electronically bound components in their original state when such compositions are absorbed into skin and reach physiological pH conditions.

  本发明涉及一种新型离子对传递系统，可用于化妆品、药品和局部营养品应用中，其中当电子给体组成物和电子受体组成物，或质子给体组成物和质子受体组成物以离子对模式结合时，其功能性能和消费者美学效果得到协同增强。在离子对键合过程中，电子给体组成物或质子受体组成物变为带正电荷，而电子受体组成物或质子给体组成物则变为带负电荷，从而以离子方式结合在一起。这样的离子对组成物在吸收到皮肤并达到生理pH条件时，释放其电子结合的成分。
• Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
  申请人：The Interthyr Corporation

  公开号：EP2399578A1

  公开（公告）日：2011-12-28

  The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with over-expression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The present invention also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. This invention also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with the Toll-like receptor overexpression or signaling.

  本发明涉及治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中Toll样受体3（TLR3）以及Toll样受体4（TLR4）和/或TLR3/TLR4信号过度表达有关的自身免疫性和/或炎症性疾病，以及相关病理。本发明还涉及苯基甲巯咪唑、甲巯咪唑衍生物和同分异构环硫代甲烷用于治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中的Toll样受体3（TLR3）以及Toll样受体4（TLR4）和/或TLR3/TLR4信号转导相关的自身免疫性和炎症性疾病。本发明还涉及治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中 Toll 样受体 3 以及 Toll 样受体 4 和/或 TLR3/TLR4 信号异常有关的疾病或病症。本发明还涉及治疗与 TLR 过度表达和信号转导相关的自身免疫炎症性病症以及趋化因子和细胞因子介导的疾病。本发明还涉及能够抑制与 Toll 样受体过度表达或信号转导相关的 IRF-3/1型 IFN/STAT/ISRE/IRF-1 通路的药物制剂。
• Non-corrosive nitrification inhibitor polar solvent formulation
  申请人：DOW AGROSCIENCES LLC

  公开号：US10173942B2

  公开（公告）日：2019-01-08

  This invention relates to stable liquid formulations of the nitrification inhibitor nitrapyrin comprising polar solvents that are stabilized with small amounts of compounds which help to reduce the tendency of polar solutions of nitrapyrin to corrode metal surfaces. Many of the formulations disclosed herein exhibit useful physical, chemical, and bioactive properties including reduced levels of corrosion when in contact with ferrous metals.

  本发明涉及硝化抑制剂硝基吡啉的稳定液体制剂，该制剂由极性溶剂组成，并用有助于降低硝基吡啉极性溶液腐蚀金属表面的倾向的少量化合物加以稳定。本文公开的许多制剂都表现出有用的物理、化学和生物活性特性，包括降低与黑色金属接触时的腐蚀程度。
• Water-in-oil emulsion containing baicalin, a xanthine base, a vitamin B3, and a polyvalent metal cation salt
  申请人：L'OREAL

  公开号：US11376205B2

  公开（公告）日：2022-07-05

  The invention provides, in the field of caring for and/or making up keratin materials, especially the skin, a composition in water-in-oil emulsion form, containing: a) a continuous oily phase, b) a discontinuous aqueous phase dispersed in the oily phase; c) at least baicalin and/or a derivative thereof and/or a plant extract containing the compound(s); d) at least one vitamin B3 and/or a derivative thereof; e) at least one xanthine base and/or a plant extract containing same; and f) at least one polyvalent cation salt.

  本发明在护理和/或妆点角质材料（尤其是皮肤）领域提供了一种油包水型乳液组合物，其中含有 a) 连续油相、 b) 分散在油相中的非连续水相； c) 至少一种黄芩苷和/或其衍生物和/或含有该化合物的植物提取物； d) 至少一种维生素 B3 和/或其衍生物； e) 至少一种黄嘌呤碱和/或含有黄嘌呤碱的植物提取物；以及 f) 至少一种多价阳离子盐。
• Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
  申请人：——

  公开号：US20040092482A1

  公开（公告）日：2004-05-13

  This invention relates to in-situ preparation of the derivatives of various hydroxy acids (HA), such as &agr;-(Alpha) Hydroxy Acids (AHA), &bgr;-(Beta) Hydroxy Acids (BHA), and Poly-Hydroxy Acids (PHA) with certain skin beneficial organic hetero-atom bases and their application in skin resurfacing (exfoliation), and in the synergistic treatment and regulation of topical disorders of skin such as skin aging, wrinkles, acne, rosacea, age-spots, canker sores, striae distensae (stretch marks), pimples, skin redness, and dry skin conditions of cracking, flaking, and scaling. Most HA derivatives produced by the in-situ method do not cause skin irritation and skin redness effects that are commonly experienced with AHA and BHA, yet there is no loss of their skin beneficial effects. These compositions can be traditional water and oil emulsions, liposomes, suspensions, colloids, solutions, masks, muds, serums, sprays, gels, lotions, creams, cleansers, and anhydrous systems, thus offering a wide choice of formulations to meet their consumer appeal and acceptance requirements.

  本发明涉及原位制备各种羟基酸（HA）的衍生物，如&agr;-（α）羟基酸（AHA）、&bgr；-(β)羟基酸 (BHA)、聚羟基酸 (PHA) 与某些对皮肤有益的有机杂原子基团的衍生物，并将其应用于焕肤（去角质）、协同治疗和调节皮肤局部疾病，如皮肤老化、皱纹、痤疮、红斑痤疮、老年斑、口腔溃疡、妊娠纹、丘疹、皮肤发红以及干性皮肤皲裂、脱皮和脱屑等。通过原位法生产的大多数 HA 衍生物不会造成 AHA 和 BHA 常见的皮肤刺激和皮肤发红现象，同时也不会失去对皮肤有益的功效。这些组合物可以是传统的水和油乳剂、脂质体、悬浮液、胶体、溶液、面膜、泥浆、精华液、喷雾剂、凝胶、乳液、膏霜、清洁剂和无水体系，因此可提供多种配方选择，以满足消费者的吸引力和接受度要求。